Endotheliopathy in COVID-19-associated coagulopathy: cross-sectional study

Lancet Haematology,the

7, e575-e582

DOI: 10.1016/s2352-3026(20)30216-7

Citation Report

#	Article	IF	Citations
1	Effects of COVID-19 on the Nervous System. Cell, 2020, 183, 16-27.e1.	13.5	526
2	Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatology, The, 2020, 2, e754-e763.	2.2	237
3	Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis, 2020, 314, 58-62.	0.4	213
4	Livedo reticularis as a presenting sign of severe acute respiratory syndrome coronavirus 2 infection. JAAD Case Reports, 2020, 6, 871-874.	0.4	20
5	An aberrant STAT pathway is central to COVID-19. Cell Death and Differentiation, 2020, 27, 3209-3225.	5.0	224
6	Convalescent Plasma for Patients With Severe Coronavirus Disease 2019 (COVID-19): A Matched Cohort Study. Clinical Infectious Diseases, 2021, 73, e208-e214.	2.9	54
7	Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. Cell, 2020, 183, 1354-1366.e13.	13.5	184
8	COVID-19 and multiorgan failure: A narrative review on potential mechanisms. Journal of Molecular Histology, 2020, 51, 613-628.	1.0	317
9	Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?. European Journal of Pharmacology, 2020, 889, 173629.	1.7	23
10	Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy. Medical Hypotheses, 2020, 143, 110197.	0.8	25
11	Vascular Manifestations of COVID-19 â€“ Thromboembolism and Microvascular Dysfunction. Frontiers in Cardiovascular Medicine, 2020, 7, 598400.	1.1	65
12	Cardiovascular Manifestations of COVID-19 Infection. Cells, 2020, 9, 2508.	1.8	142
13	Endothelial Damage in Acute Respiratory Distress Syndrome. International Journal of Molecular Sciences, 2020, 21, 8793.	1.8	110
14	COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 401-414.	1.1	82
15	Prevalence of readily detected amyloid blood clots in â€˜unclottedâ€™ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report. Cardiovascular Diabetology, 2020, 19, 193.	2.7	44
16	Cerebral microhaemorrhage in COVID-19: a critical illness related phenomenon?. Stroke and Vascular Neurology, 2020, 5, e000652.	1.5	41
17	Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13. Frontiers in Immunology, 2020, 11, 610696.	2.2	62
18	Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure. Platelets, 2021, 32, 560-567.	1.1	31

#	Article	IF	Citations
19	Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19. Respiratory Medicine, 2020, 175, 106188.	1.3	33
20	COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. Frontiers in Immunology, 2020, 11, 589474.	2.2	46
21	SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020078.	0.5	5
22	Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology, 2020, 225, 152001.	0.8	120
23	Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes. International Journal of Molecular Sciences, 2020, 21, 5168.	1.8	135
24	COVIDâ€19 coagulopathy: An inâ€depth analysis of the coagulation system. European Journal of Haematology, 2020, 105, 741-750.	1.1	93
25	Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. European Respiratory Journal, 2020, 56, 2002049.	3.1	168
26	Preliminary Post-Mortem COVID-19 Evidence of Endothelial Injury and Factor VIII Hyperexpression. Diagnostics, 2020, 10, 575.	1.3	58
27	Role of testosterone in COVID-19 patients â€“ A double-edged sword?. Medical Hypotheses, 2020, 144, 110287.	0.8	21
28	Severe COVID-19 Is a Microvascular Disease. Circulation, 2020, 142, 1609-1611.	1.6	197
29	COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H793-H796.	1.5	18
30	Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. European Respiratory Journal, 2020, 56, 2003006.	3.1	172
31	Risk of venous thromboembolism in patients with COVIDâ€19: A systematic review and metaâ€analysis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1178-1191.	1.0	366
32	Routine haematological parameters in COVID-19 prognosis. Lancet Haematology,the, 2020, 7, e709.	2.2	8
33	Immune responses during COVID-19 infection. OncoImmunology, 2020, 9, 1807836.	2.1	103
34	The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflammation Research, 2020, 69, 1181-1189.	1.6	302
35	Modulation of endothelial organelle size as an antithrombotic strategy. Journal of Thrombosis and Haemostasis, 2020, 18, 3296-3308.	1.9	16
36	Hematological Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced Coagulopathy. Journal of Clinical Medicine, 2020, 9, 2875.	1.0	30

#	Article	IF	Citations
37	The Enigma of Endothelium in COVID-19. Frontiers in Physiology, 2020, 11, 989.	1.3	70
38	Deciphering SARS-CoV-2 Virologic and Immunologic Features. International Journal of Molecular Sciences, 2020, 21, 5932.	1.8	28
39	The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System. Frontiers in Cardiovascular Medicine, 2020, 7, 602183.	1.1	26
40	Covid-19 cytokine storm in pulmonary tissue: Anatomopathological and immunohistochemical findings. Respiratory Medicine Case Reports, 2020, 31, 101292.	0.2	16
41	A cross-talk between epithelium and endothelium mediates human alveolarâ€“capillary injury during SARS-CoV-2 infection. Cell Death and Disease, 2020, 11, 1042.	2.7	83
42	Circulating markers of angiogenesis and endotheliopathy in COVIDâ€19. Pulmonary Circulation, 2020, 10, 1-4.	0.8	103
43	The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. International Journal of Molecular Sciences, 2020, 21, 9309.	1.8	27
44	Immune Mechanisms in Cardiovascular Diseases Associated With Viral Infection. Frontiers in Immunology, 2020, 11, 570681.	2.2	29
45	Hyperthrombotic Milieu in COVID-19 Patients. Cells, 2020, 9, 2392.	1.8	27
46	Erythrocyte, Platelet, Serum Ferritin, and P-Selectin Pathophysiology Implicated in Severe Hypercoagulation and Vascular Complications in COVID-19. International Journal of Molecular Sciences, 2020, 21, 8234.	1.8	70
47	Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematology,the, 2020, 7, e553-e555.	2.2	122
48	COVID-19: what the clinician should know about post-mortem findings. Intensive Care Medicine, 2021, 47, 86-89.	3.9	34
49	The Dysfunction is in the Details: Neurovascular Changes in COVID-19. Canadian Journal of Neurological Sciences, 2021, 48, 1-2.	0.3	3
50	Large-Scale Multi-omic Analysis of COVID-19 Severity. Cell Systems, 2021, 12, 23-40.e7.	2.9	438
51	COVID-19 â€“ A vascular disease. Trends in Cardiovascular Medicine, 2021, 31, 1-5.	2.3	254
52	Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis, 2021, 24, 145-157.	3.7	211
53	Association of anticoagulation dose and survival in hospitalized COVIDâ€19 patients: A retrospective propensity scoreâ€weighted analysis. European Journal of Haematology, 2021, 106, 165-174.	1.1	69
54	The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology, 2021, 88, 15-27.	1.9	331

#	Article	IF	Citations
55	Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients. Journal of Thrombosis and Thrombolysis, 2021, 51, 971-977.	1.0	62
56	The ADAMTS13â€von Willebrand factor axis in COVIDâ€19 patients. Journal of Thrombosis and Haemostasis, 2021, 19, 513-521.	1.9	176
57	New Horizons: Does Mineralocorticoid Receptor Activation by Cortisol Cause ATP Release and COVID-19 Complications?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 622-635.	1.8	17
58	Early changes in laboratory parameters are predictors of mortality and ICU admission in patients with COVID-19: a systematic review and meta-analysis. Medical Microbiology and Immunology, 2021, 210, 33-47.	2.6	41
59	Prothrombotic changes in patients with COVIDâ€19 are associated with disease severity and mortality. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 132-141.	1.0	69
60	COVID-19 and stroke: A review. Brain Hemorrhages, 2021, 2, 76-83.	0.4	36
61	Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nature Immunology, 2021, 22, 19-24.	7.0	101
62	Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nature Reviews Cardiology, 2021, 18, 194-209.	6.1	304
63	ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVIDâ€19. Journal of Internal Medicine, 2021, 289, 688-699.	2.7	26
64	Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. Journal of NeuroInterventional Surgery, 2021, 13, 202-206.	2.0	75
65	Biomarkers for the clinical development of antiviral therapies. Cytometry Part B - Clinical Cytometry, 2021, 100, 19-32.	0.7	2
66	Harmonizing hypercoagulable heterogeneity: Baseline VTE risk in COVIDâ€19. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 9-10.	1.0	1
67	Retrospective Analyses Associate Hemostasis Activation Biomarkers With Poor Outcomes in Patients With COVID-19. American Journal of Clinical Pathology, 2021, 155, 498-505.	0.4	12
68	Laboratory markers associated with COVIDâ€19 progression in patients with or without comorbidity: A retrospective study. Journal of Clinical Laboratory Analysis, 2021, 35, e23644.	0.9	27
69	Biomimetic Human Disease Model of SARSâ€CoVâ€2â€Induced Lung Injury and Immune Responses on Organ Chip System. Advanced Science, 2021, 8, 2002928.	5.6	119
70	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021, 116, 102560.	3.0	127
71	Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. Annals of Hematology, 2021, 100, 37-43.	0.8	45
72	Discordant <scp>antiâ€SARSâ€CoV</scp>â€2 spike protein and <scp>RNA</scp> staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein. Journal of Cutaneous Pathology, 2021, 48, 47-52.	0.7	43

#	Article	IF	Citations
73	Hemostatic alterations in COVID-19. Haematologica, 2021, 106, 1472-1475.	1.7	34
74	Coronavirus disease (COVID-19) and the endothelium. , 2021, , 205-211.		0
75	COVID-19 and the ethnicity link â€“ is there a photochemical link?. Photochemical and Photobiological Sciences, 2021, 20, 183-188.	1.6	4
76	Clinical risk stratification in COVIDâ€19: the need for a revised approach?. Pulmonary Circulation, 2021, 11, 1-4.	0.8	4
77	RNA-Based COVID-19 Vaccine Candidates with Clinical Phase Trials in Progress. Turkish Journal of Medical Sciences, 2021, , .	0.4	0
78	Post-COVID syndrome: pulmonary complications. Turkish Journal of Medical Sciences, 2021, 51, 3359-3371.	0.4	23
79	Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 2020, 7, 599334.	1.1	15
80	Coronavirus Pneumonia and Pulmonary Thromboembolism. BIO Integration, 2021, 1, .	0.9	1
83	Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVIDâ€19 outcomes. Clinical and Translational Medicine, 2021, 11, e268.	1.7	15
84	Cardiovascular Health and Disease in the Context of COVID-19. Cardiology Research, 2021, 12, 67-79.	0.5	16
85	Thromboplasminflammation in COVID-19 coagulopathy. Japanese Journal of Thrombosis and Hemostasis, 2021, 32, 406-409.	0.1	0
86	ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in Critically Ill COVID-19 Patients. Cells, 2021, 10, 186.	1.8	81
87	Clinical and laboratory features of hypercoagulability in COVID-19 and other respiratory viral infections amongst predominantly younger adults with few comorbidities. Scientific Reports, 2021, 11, 1793.	1.6	28
88	COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax, 2021, 76, 412-420.	2.7	239
89	Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients. TH Open, 2021, 05, e89-e103.	0.7	22
90	COVID-19-associated thrombotic microangiopathy (TMA). Japanese Journal of Thrombosis and Hemostasis, 2021, 32, 307-314.	0.1	0
91	Transcriptomic Analysis of Respiratory Tissue and Cell Line Models to Examine Glycosylation Machinery during SARS-CoV-2 Infection. Viruses, 2021, 13, 82.	1.5	5
92	Does COVID-19 Provide a Clue for Thrombosis in ITP?. Seminars in Thrombosis and Hemostasis, 2021, 47, 463-466.	1.5	4

#	Article	IF	Citations
93	Venous thromboembolic complications in patients with severe and extremely severe COVID-19. Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya, 2021, , 41.	0.2	2
94	Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: Similarities, Differences, and Implications for Therapy. Viruses, 2021, 13, 161.	1.5	17
95	Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C) under the Setting of COVID-19: A Review of Clinical Presentation, Workup and Management. Infectious Diseases: Research and Treatment, 2021, 14, 117863372110266.	0.7	12
96	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. International Journal of Hematology, 2021, 113, 330-336.	0.7	16
97	Determinants of Increased Fibrinogen in COVID-19 Patients With and Without Diabetes and Impaired Fasting Glucose. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962199644.	0.7	3
99	Role of Cell Adhesion Molecules for Prognosis of Disease Development of Patients With and Without COVID-19 in the Emergency Department. Journal of Infectious Diseases, 2021, 223, 1497-1499.	1.9	10
100	COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura. IDCases, 2021, 26, e01256.	0.4	10
101	Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110089.	0.7	16
102	Anemia in patients with Covid-19: pathogenesis and clinical significance. Clinical and Experimental Medicine, 2021, 21, 239-246.	1.9	78
104	Pulmonary pathology of COVID-19: a review of autopsy studies. Current Opinion in Pulmonary Medicine, 2021, 27, 184-192.	1.2	47
105	A review of the pathological mechanisms and clinical implications of coagulopathy in COVID-19. Journal of Applied Hematology, 2021, 12, 66.	0.1	0
107	A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Advances, 2021, 5, 1164-1177.	2.5	241
108	MRâ€proADM as marker of endotheliitis predicts COVIDâ€19 severity. European Journal of Clinical Investigation, 2021, 51, e13511.	1.7	34
110	Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders. Molecules, 2021, 26, 856.	1.7	49
111	SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics. Expert Review of Proteomics, 2021, 18, 105-118.	1.3	10
112	Thrombocytopathies: Not Just Aggregation Defectsâ€"The Clinical Relevance of Procoagulant Platelets. Journal of Clinical Medicine, 2021, 10, 894.	1.0	15
114	Development and validation of clinical prediction model to estimate the probability of death in hospitalized patients with COVIDâ€19: Insights from a nationwide database. Journal of Medical Virology, 2021, 93, 3015-3022.	2.5	20
115	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. Journal of Microbiology, Immunology and Infection, 2021, 54, 37-45.	1.5	5

#	Article	IF	Citations
116	d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019. Critical Care Medicine, 2021, 49, e500-e511.	0.4	35
117	Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review). Molecular Medicine Reports, 2021, 23, .	1.1	6
118	Assessment of Platelet Thrombus Formation under Flow Conditions in Adult Patients with COVID-19: An Observational Study. Thrombosis and Haemostasis, 2021, 121, 1087-1096.	1.8	9
119	The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Critical Care Medicine, 2021, 49, 598-622.	0.4	49
120	von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019. Critical Care Medicine, 2021, 49, e512-e520.	0.4	56
121	COVIDâ€19â€induced endotheliitis: emerging evidence and possible therapeutic strategies. British Journal of Haematology, 2021, 193, 43-51.	1.2	49
122	American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Advances, 2021, 5, 872-888.	2.5	310
124	COVID-19 induces a hyperactive phenotype in circulating platelets. PLoS Biology, 2021, 19, e3001109.	2.6	108
125	Intermediateâ€dose anticoagulation, aspirin, and inâ€hospital mortality in <scp>COVID</scp>â€19: A propensity scoreâ€matched analysis. American Journal of Hematology, 2021, 96, 471-479.	2.0	129
126	COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies. Molecular Biology Reports, 2021, 48, 2917-2928.	1.0	7
127	Understanding of COVID-19 Pathology: Much More Attention to Plasma Proteins. Frontiers in Immunology, 2021, 12, 656099.	2.2	3
129	Arterial stiffness in acute COVIDâ€19 and potential associations with clinical outcome. Journal of Internal Medicine, 2021, 290, 437-443.	2.7	55
131	Thrombotic thrombocytopenic purpura (TTP) response following COVIDâ€19 infection: Implications for the ADAMTSâ€13â€"von Willebrand factor axis. Journal of Thrombosis and Haemostasis, 2021, 19, 1130-1139.	1.9	10
132	Post-acute COVID-19 syndrome. Nature Medicine, 2021, 27, 601-615.	15.2	3,051
133	COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Heart and Lung: Journal of Acute and Critical Care, 2021, 50, 357-360.	0.8	48
134	Practical Recommendations Relevant to the Use of Resistance Training for COVID-19 Survivors. Frontiers in Physiology, 2021, 12, 637590.	1.3	20
136	Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology. Frontiers in Cardiovascular Medicine, 2021, 8, 649922.	1.1	15
137	Endothelial dysfunction in COVID-19 calls for immediate attention: the emerging roles of the endothelium in inflammation caused by SARS-CoV-2. Frontiers of Medicine, 2021, 15, 638-643.	1.5	9

#	Article	IF	Citations
138	Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status. Journal of Autoimmunity, 2021, 118, 102596.	3.0	27
139	ICAM-1 levels in patients with covid-19 with diabetic foot ulcers: A prospective study in southeast asia. Annals of Medicine and Surgery, 2021, 63, 102171.	0.5	10
140	Consequences of coronavirus infections for primitive and mature hematopoietic cells: new insights and why it matters. Current Opinion in Hematology, 2021, 28, 231-242.	1.2	2
142	Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions. Biomedicines, 2021, 9, 279.	1.4	20
143	Severe Acute Respiratory Syndromeâ€"Associated Coronavirus 2 Infection and Organ Dysfunction in the ICU: Opportunities for Translational Research. , 2021, 3, e0374.		20
144	Sexâ€based differences in severity and mortality in COVIDâ€19. Reviews in Medical Virology, 2021, 31, e2223.	3.9	78
145	Plateletâ€activating immune complexes identified in critically ill COVIDâ€19 patients suspected of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2021, 19, 1342-1347.	1.9	74
146	SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm. Journal of Clinical Medicine, 2021, 10, 1064.	1.0	8
147	Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients. Scientific Reports, 2021, 11, 7792.	1.6	28
148	Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C. Medical Hypotheses, 2021, 149, 110537.	0.8	5
149	The aging endothelium. Vascular Biology (Bristol, England), 2021, 3, R35-R47.	1.2	20
150	SARS-CoV-2 induced intestinal responses with a biomimetic human gut-on-chip. Science Bulletin, 2021, 66, 783-793.	4.3	91
151	Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. Seminars in Thrombosis and Hemostasis, 2021, 47, 400-418.	1.5	75
152	Neuropathogenesis of acute coronavirus disease 2019. Current Opinion in Neurology, 2021, 34, 417-422.	1.8	14
153	COVID-19 and thrombosis: From bench to bedside. Trends in Cardiovascular Medicine, 2021, 31, 143-160.	2.3	152
154	Thromboembolic Complications in Covid-19: From Clinical Scenario to Laboratory Evidence. Life, 2021, 11, 395.	1.1	2
155	Comparative outcomes between COVID-19 and influenza patients placed on veno-venous extracorporeal membrane oxygenation for severe ARDS. American Journal of Surgery, 2022, 223, 388-394.	0.9	17
156	An Early Unexpected Immune Thrombotic Thrombocytopenic Purpura Relapse Associated with SARS-CoV-2 Infection: A Case Report and Literature Review. Acta Haematologica, 2021, 144, 678-682.	0.7	8

#	Article	IF	Citations
157	Canâ€™t Dissolve Me Now: A COVID-19 Provoked Venous Thromboembolism Breaks Through Apixaban: Case Report. Clinical Practice and Cases in Emergency Medicine, 2021, 2, 202-205.	0.1	1
158	Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1613.	3.8	19
160	Novel understanding of septic pathophysiology and neutrophil extracellular traps. Okayama Igakkai Zasshi, 2021, 133, 10-22.	0.0	0
161	Coronavirus disease-19: The multi-level, multi-faceted vasculopathy. Atherosclerosis, 2021, 322, 39-50.	0.4	32
162	Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med, 2021, 2, 411-422.e5.	2.2	41
163	Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease. Frontiers in Immunology, 2021, 12, 676756.	2.2	15
164	Silibinin as potential tool against <scp>SARSâ€Cov</scp>â€2: In silico spike <scp>receptorâ€binding</scp> domain and main protease molecular docking analysis, and in vitro endothelial protective effects. Phytotherapy Research, 2021, 35, 4616-4625.	2.8	32
165	Endothelial cells and SARS-CoV-2: An intimate relationship. Vascular Pharmacology, 2021, 137, 106829.	1.0	45
166	Associations of D-Dimer with Computed Tomographic Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study. Annals of the American Thoracic Society, 2021, 18, 1839-1848.	1.5	3
167	Role of pirfenidone in TGF-Î² pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a theoretical perspective. Pharmacological Reports, 2021, 73, 712-727.	1.5	30
169	Acute Ischemic Stroke During the Convalescent Phase of Asymptomatic COVID-2019 Infection in Men. JAMA Network Open, 2021, 4, e217498.	2.8	50
171	Neurological update: COVID-19. Journal of Neurology, 2021, 268, 4379-4387.	1.8	25
172	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nature Reviews Immunology, 2021, 21, 319-329.	10.6	594
173	Intracranial Hemorrhage in COVID-19 Patients. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105603.	0.7	25
175	Spatial mapping of SARS-CoV-2 and H1N1 lung injury identifies differential transcriptional signatures. Cell Reports Medicine, 2021, 2, 100242.	3.3	38
176	Platelet Count Rose While D-Dimer Levels Dropped as Deaths and Thrombosis Declinedâ€”An Observational Study on Anticoagulation Shift in COVID-19. Thrombosis and Haemostasis, 2021, 121, 1610-1621.	1.8	14
177	Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nature Reviews Microbiology, 2021, 19, 425-441.	13.6	202
178	Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 388-402.	1.2	51

#	Article	IF	Citations
180	An autopsy study of the spectrum of severe COVID-19 in children: From SARS to different phenotypes of MIS-C. EClinicalMedicine, 2021, 35, 100850.	3.2	83
181	Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory response at the maternal-fetal interface. Med, 2021, 2, 591-610.e10.	2.2	122
182	Postâ€adenoviralâ€based COVIDâ€19 vaccines thrombosis: A proposed mechanism. Journal of Thrombosis and Haemostasis, 2021, 19, 1831-1832.	1.9	20
183	Endothelial Dysfunction in the Brain. Stroke, 2021, 52, 1895-1904.	1.0	50
184	How we approach thrombosis risk in children with COVIDâ€19 infection and MISâ€C. Pediatric Blood and Cancer, 2021, 68, e29049.	0.8	25
185	Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?. Journal of Infection, 2021, 82, e20-e22.	1.7	3
186	COVID-19 Vasculopathy: Mounting Evidence for an Indirect Mechanism of Endothelial Injury. American Journal of Pathology, 2021, 191, 1374-1384.	1.9	78
187	Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course. Frontiers in Immunology, 2021, 12, 684142.	2.2	25
188	Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Science Immunology, 2021, 6, .	5.6	153
189	Biomaterial-based immunoengineering to fight COVID-19 and infectious diseases. Matter, 2021, 4, 1528-1554.	5.0	21
190	Between inflammation and thrombosis: endothelial cells in COVID-19. European Respiratory Journal, 2021, 58, 2100377.	3.1	86
191	Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVIDâ€19: A singleâ€center prospective longitudinal study. Journal of Thrombosis and Haemostasis, 2021, 19, 1546-1557.	1.9	45
192	Microvascular Dysfunction in Patients with Critical Covid-19, a Pilot Study. Shock, 2021, 56, 964-968.	1.0	16
193	Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thrombosis Research, 2021, 201, 100-112.	0.8	42
194	Vascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1760-1773.	1.1	82
195	Interplay between inflammation and thrombosis in cardiovascular pathology. Nature Reviews Cardiology, 2021, 18, 666-682.	6.1	337
196	Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. European Journal of Pharmacology, 2021, 898, 173988.	1.7	31
197	Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. Vascular Medicine, 2021, 26, 626-632.	0.8	26

#	Article	IF	Citations
199	Stroke and neurointervention in the COVID-19 pandemic: a narrative review. Expert Review of Medical Devices, 2021, 18, 1-9.	1.4	8
200	Impact of presymptomatic COVID-19 on vascular and skeletal muscle function: a case study. Journal of Applied Physiology, 2021, 130, 1961-1970.	1.2	17
201	Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?. Regenerative Medicine, 2021, 16, 477-494.	0.8	2
205	Development of sacral/buttock retiform purpura as an ominous presenting sign of COVID â€19 and clinical and histopathologic evolution during severe disease course. Journal of Cutaneous Pathology, 2021, 48, 1166-1172.	0.7	6
206	Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Medicine, 2021, 47, 899-902.	3.9	38
207	A review on SARS-CoV-2 and stroke pathogenesis and outcome. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, 63.	0.4	11
208	Relevant mediators involved in and therapies targeting the inflammatory response induced by activation of the NLRP3 inflammasome in ischemic stroke. Journal of Neuroinflammation, 2021, 18, 123.	3.1	49
209	Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design. Acta Pharmaceutica Sinica B, 2021, 11, 3060-3091.	5.7	74
210	Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock, 2022, 57, 95-105.	1.0	43
211	Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. Frontiers in Immunology, 2021, 12, 649122.	2.2	34
212	Pulmonary Thrombosis and Thromboembolism in COVID-19. Chest, 2021, 160, 1471-1480.	0.4	92
213	Immunothrombosis in Acute Respiratory Dysfunction of COVID-19. Frontiers in Immunology, 2021, 12, 651545.	2.2	17
214	Modeling NO Biotransport in Brain Using a Space-Fractional Reaction-Diffusion Equation. Frontiers in Physiology, 2021, 12, 644149.	1.3	2
215	At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease. Current Opinion in Pulmonary Medicine, 2021, 27, 342-349.	1.2	9
216	Endothelial dysfunction and its critical role in COVIDâ€19â€associated coagulopathy: Defibrotide as an endotheliumâ€protective, targeted therapy. EJHaem, 2021, 2, 680-681.	0.4	3
217	Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19. Trends in Pharmacological Sciences, 2021, 42, 431-433.	4.0	20
218	A single transcript for the prognosis of disease severity in COVID-19 patients. Scientific Reports, 2021, 11, 12174.	1.6	9
219	Ischemic Stroke, Inflammation, and Endotheliopathy in COVID-19 Patients. Stroke, 2021, 52, e233-e238.	1.0	31

#	Article	IF	Citations
220	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. Cardiovascular Drugs and Therapy, 2022, 36, 547-560.	1.3	37
222	Letter in response to: circulating von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis, 2021, 24, 413-415.	3.7	7
223	Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. PLoS Pathogens, 2021, 17, e1009634.	2.1	43
224	COVID-19 and Delayed Cerebral Ischemiaâ€"More in Common Than First Meets the Eye. Journal of Clinical Medicine, 2021, 10, 2646.	1.0	3
225	COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis, 2021, 24, 755-788.	3.7	114
226	Role of von Willebrand Factor in COVID-19 Associated Coagulopathy. journal of applied laboratory medicine, The, 2021, 6, 1305-1315.	0.6	26
227	Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis. International Journal of Infectious Diseases, 2022, 117, 267-273.	1.5	24
228	Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?. Case Reports in Immunology, 2021, 2021, 1-5.	0.2	6
229	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opinion on Therapeutic Targets, 2021, 25, 423-433.	1.5	6
230	Dying of VOC-202012/01 â€" multimodal investigations in a death case of the SARS-CoV-2 variant. International Journal of Legal Medicine, 2022, 136, 193-202.	1.2	3
231	Inflammation, Infection and Venous Thromboembolism. Circulation Research, 2021, 128, 2017-2036.	2.0	94
232	Multisystem inflammatory syndrome in children (MISâ€C) and the prothrombotic state: Coagulation profiles and rotational thromboelastometry in a MISâ€C cohort. Journal of Thrombosis and Haemostasis, 2021, 19, 1764-1770.	1.9	26
233	Immunofibrotic drivers of impaired lung function in postacute sequelae of SARS-CoV-2 infection. JCI Insight, 2021, 6, .	2.3	49
234	Hypertension is the major predictor of poor outcomes among inpatients with COVID-19 infection in the UK: a retrospective cohort study. BMJ Open, 2021, 11, e047561.	0.8	11
235	Coronary microvascular dysfunction pathophysiology in COVIDâ€19. Microcirculation, 2021, 28, e12718.	1.0	37
236	COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on â€œTwo-Path Unifying Theoryâ€•of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy. Vascular Health and Risk Management, 2021, Volume 17, 273-298.	1.0	18
237	THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021045.	0.5	16
238	ADAMTS13 regulation of VWF multimer distribution in severe COVIDâ€19. Journal of Thrombosis and Haemostasis, 2021, 19, 1914-1921.	1.9	58

#	Article	IF	Citations
239	Plasma Von Willebrand Factor Levels Predict Survival in COVID-19 Patients Across the Entire Spectrum of Disease Severity. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 333-340.	0.3	7
240	Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clinical Microbiology and Infection, 2021, 27, 892-896.	2.8	85
241	Immunothrombosis: a COVIDâ€19 concerto. British Journal of Haematology, 2021, 194, 491-493.	1.2	2
242	Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study. Clinical Drug Investigation, 2021, 41, 723-732.	1.1	11
244	Association of obesity with venous thromboembolism and myocardial injury in COVID-19. Obesity Research and Clinical Practice, 2021, 15, 512-514.	0.8	7
245	COVIDâ€19 and ischemic stroke. European Journal of Neurology, 2021, 28, 3826-3836.	1.7	55
246	Low-dose aspirin for early COVID-19: does the early bird catch the worm?. Expert Opinion on Investigational Drugs, 2021, 30, 785-788.	1.9	13
247	Platelet activation in critically ill COVID-19 patients. Annals of Intensive Care, 2021, 11, 113.	2.2	61
248	A mild deficiency of ADAMTS13 is associated with severity in COVID-19: comparison of the coagulation profile in critically and noncritically ill patients. Blood Coagulation and Fibrinolysis, 2021, 32, 458-467.	0.5	9
249	Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone. Diagnostics, 2021, 11, 1249.	1.3	18
250	Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study. Life Sciences, 2021, 277, 119634.	2.0	26
251	Non-arteritic anterior ischaemic optic neuropathy sequential to SARS-CoV-2 virus pneumonia: preventable by endothelial protection?. BMJ Case Reports, 2021, 14, e240542.	0.2	12
252	SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro. Frontiers in Cellular and Infection Microbiology, 2021, 11, 701278.	1.8	95
253	COVIDâ€19 and immunothrombosis: emerging understanding and clinical management. British Journal of Haematology, 2021, 194, 518-529.	1.2	42
254	Mechanisms of immunothrombosis in COVID-19. Current Opinion in Hematology, 2021, 28, 445-453.	1.2	30
255	Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease. Pharmaceuticals, 2021, 14, 751.	1.7	13
258	L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus. JCI Insight, 2021, 6, .	2.3	31
259	Pathophysiology of COVID-19-associated acute kidney injury. Nature Reviews Nephrology, 2021, 17, 751-764.	4.1	280

#	Article	IF	Citations
260	A serum proteome signature to predict mortality in severe COVID-19 patients. Life Science Alliance, 2021, 4, e202101099.	1.3	62
261	The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review. International Journal of Molecular Sciences, 2021, 22, 7942.	1.8	20
262	Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. Experimental and Molecular Medicine, 2021, 53, 1116-1123.	3.2	116
263	Endothelium Activation Markers in Severe Hospitalized COVID-19 Patients: Role in Mortality Risk Prediction. TH Open, 2021, 05, e253-e263.	0.7	16
264	Post-COVID-19 acute sarcopenia: physiopathology and management. Aging Clinical and Experimental Research, 2021, 33, 2887-2898.	1.4	116
265	A Comparison of the Clinical, Viral, Pathologic, and Immunologic Features of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus 2019 (COVID-19) Diseases. Archives of Pathology and Laboratory Medicine, 2021, 145, 1194-1211.	1.2	9
266	Pathomorphological changes in pulmonary vessels at different terms of lethal outcomes of patients with COVID-19. Medical Herald of the South of Russia, 2021, 12, 54-61.	0.2	1
267	Clinical patterns of endothelial damage and thrombotic events in two patients with COVIDâ€19: A case report. Clinical Case Reports (discontinued), 2021, 9, e04406.	0.2	0
268	Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets. Blood, 2021, 138, 1481-1489.	0.6	66
269	SARS-CoV-2: is there neuroinvasion?. Fluids and Barriers of the CNS, 2021, 18, 32.	2.4	43
270	Pulmonary infarcts in COVID-19. Clinical Imaging, 2021, 80, 158-159.	0.8	1
271	SARS-CoV-2 Poorly Replicates in Cells of the Human Blood-Brain Barrier Without Associated Deleterious Effects. Frontiers in Immunology, 2021, 12, 697329.	2.2	26
272	Problems of Pathogenesis and Pathogenetic Therapy of COVID-19 from the Perspective of the General Theory of Pathological Systems (General Pathological Processes). International Journal of Molecular Sciences, 2021, 22, 7582.	1.8	27
273	Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thrombosis Research, 2021, 203, 163-171.	0.8	52
274	COVID-19 and Acute Coronary Syndromes: From Pathophysiology to Clinical Perspectives. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	1.9	25
275	Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) Landscape. Biomedicines, 2021, 9, 997.	1.4	15
276	Physician experiences in management of COVIDâ€19â€associated coagulopathy in pregnancy: Communication from the ISTH SSC Subcommittee on Women's Health Issues in Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2021, 19, 2539-2545.	1.9	16
277	COVIDâ€19 and coagulopathy. Clinical Respiratory Journal, 2021, 15, 1259-1274.	0.6	25

#	Article	IF	Citations
278	Thrombotic and Hypercoagulability Complications of COVID-19: An Update. Journal of Blood Medicine, 2021, Volume 12, 785-793.	0.7	14
279	BPIFB4 Circulating Levels and Its Prognostic Relevance in COVID-19. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1775-1783.	1.7	9
280	Current knowledge of COVID-19: Advances, challenges and future perspectives. Biosafety and Health, 2021, 3, 202-209.	1.2	4
281	Age-Associated Neurological Complications of COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 653694.	1.7	28
282	Potential protective mechanisms of green tea polyphenol EGCG against COVID-19. Trends in Food Science and Technology, 2021, 114, 11-24.	7.8	96
283	Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19â€"Mechanisms and Therapeutic Targets. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-15.	1.9	66
284	Tailoring glucocorticoids in patients with severe COVID-19: a narrative review. Annals of Translational Medicine, 2021, 9, 1261-1261.	0.7	3
285	Retinal manifestations in patients with SARS-CoV-2 infection and pathogenetic implications: a systematic review. International Ophthalmology, 2022, 42, 323-336.	0.6	34
286	Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer. Annals of the Rheumatic Diseases, 2021, 80, 1105-1107.	0.5	12
288	Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, .	0.6	10
290	Thromboprophylaxis in COVID-19 â€“ Rationale and considerations. Advances in Biological Regulation, 2021, 81, 100819.	1.4	2
291	Alterations in platelets during SARS-CoV-2 infection. Platelets, 2022, 33, 192-199.	1.1	14
292	Microcirculation Disorders in Patients with Severe COVID-19. Messenger of Anesthesiology and Resuscitation, 2021, 18, 7-19.	0.1	2
293	Specific Features of the Coagulopathy Signature in Severe COVID-19 Pneumonia. Frontiers in Medicine, 2021, 8, 675191.	1.2	7
294	Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovascular Diabetology, 2021, 20, 172.	2.7	271
295	Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain, 2021, 144, 3576-3588.	3.7	101
296	Elevated plasma ICAM1 levels predict 28-day mortality inÂcirrhotic patients with COVID-19 or bacterial sepsis. JHEP Reports, 2021, 3, 100303.	2.6	19
297	Comparison of renal replacement therapy and renal recovery before and during the COVID-19 pandemic: a single center observational study. Minerva Anestesiologica, 2021, 87, 1209-1216.	0.6	1

#	Article	IF	Citations
298	SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Bioscience Reports, 2021, 41, .	1.1	104
299	Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience. , 2021, 3, e0517.		10
300	ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19. Thrombosis Research, 2021, 204, 138-140.	0.8	27
301	C-C motive chemokine ligand 2 and thromboinflammation in COVID-19-associated pneumonia: A retrospective study. Thrombosis Research, 2021, 204, 88-94.	0.8	5
302	COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles. Journal of Thrombosis and Thrombolysis, 2021, 52, 1010-1019.	1.0	10
303	Age-Associated Increase in Thrombogenicity and Its Correlation with von Willebrand Factor. Journal of Clinical Medicine, 2021, 10, 4190.	1.0	10
304	Elevated von Willebrand Factor Antigen Is an Early Predictor of Mortality and Prolonged Length of Stay for Coronavirus Disease 2019 (COVID-19) Inpatients. Archives of Pathology and Laboratory Medicine, 2022, 146, 34-37.	1.2	13
305	Nuts and bolts of COVID-19 associated coagulopathy: the essentials for management and treatment. Postgraduate Medicine, 2021, 133, 1-13.	0.9	4
306	Platelets amplify endotheliopathy in COVID-19. Science Advances, 2021, 7, eabh2434.	4.7	78
307	Interleukin-1RA Mitigates SARS-CoV-2â€“Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2773-2785.	1.1	20
308	Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19. JCI Insight, 2021, 6, .	2.3	35
309	Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). Cardiovascular Research, 2021, 117, 2705-2729.	1.8	95
310	Association of <scp>COVID</scp>â€19 with impaired endothelial glycocalyx, vascular function andÂmyocardial deformation 4 months after infection. European Journal of Heart Failure, 2021, 23, 1916-1926.	2.9	81
311	Hemodynamic Dysfunctions in COVID-19 Patients. Research, Society and Development, 2021, 10, e111101220323.	0.0	1
312	Further Findings Concerning Endothelial Damage in COVID-19 Patients. Biomolecules, 2021, 11, 1368.	1.8	7
313	Better Anticoagulated Than Not! Hypercoagulability in COVID-19. JCO Oncology Practice, 2021, 17, 522-523.	1.4	1
314	Unraveling the role of liver sinusoidal endothelial cells in COVID-19 liver injury. Journal of Hepatology, 2021, 75, 503-505.	1.8	5
315	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Advances, 2021, 5, 3951-3959.	2.5	49

#	Article	IF	Citations
316	Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. EClinicalMedicine, 2021, 39, 101069.	3.2	48
317	Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Frontiers in Immunology, 2021, 12, 742941.	2.2	81
318	The immune response to SARS-CoV-2 and COVID-19 immunopathology â€“ Current perspectives. Pulmonology, 2021, 27, 423-437.	1.0	118
319	Soluble IL-2R Levels Predict in-Hospital Mortality in COVID-19 Patients with Respiratory Failure. Journal of Clinical Medicine, 2021, 10, 4242.	1.0	8
320	High immature platelet fraction with reduced platelet count on hospital admission. Can it be useful for COVIDâ€19 diagnosis?. International Journal of Laboratory Hematology, 2021, 43, 1319-1324.	0.7	7
321	Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: Potential role in prevention and management of COVID-19. Journal of Pharmaceutical Analysis, 2022, 12, 29-34.	2.4	34
322	Interdisciplinary Approach to Thrombosis Management in COVID-19 at a Large Academic Center. JCO Oncology Practice, 2021, 17, 517-521.	1.4	2
323	Elevated Serum Levels of Progranulin and Soluble Vascular Cell Adhesion Molecule-1 in Patients with COVID-19. Journal of Inflammation Research, 2021, Volume 14, 4785-4794.	1.6	14
324	COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction. JCI Insight, 2021, 6, .	2.3	57
325	Autopsy-Based Pulmonary and Vascular Pathology: Pulmonary Endotheliitis and Multi-Organ Involvement in COVID-19 Associated Deaths. Respiration, 2022, 101, 155-165.	1.2	25
326	Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal of Hepatology, 2021, 75, 647-658.	1.8	67
327	Potential biomarkers for the early prediction of SARS-COV-2 disease outcome. Microbial Pathogenesis, 2021, 158, 105057.	1.3	18
328	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. Journal of Thrombosis and Haemostasis, 2021, 19, 2546-2553.	1.9	208
329	The COVID-19 Patient in the Surgical Intensive Care Unit. Surgical Clinics of North America, 2021, 102, 1-21.	0.5	5
330	Biomarkers Associated with Failure of Liberation from Oxygen Therapy in Severe COVID-19: A Pilot Study. Journal of Personalized Medicine, 2021, 11, 974.	1.1	4
331	Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19). Microvascular Research, 2021, 137, 104188.	1.1	52
332	Vessel wall magnetic resonance imaging in COVIDâ€19â€associated cryptogenic ischemic stroke. European Journal of Neurology, 2022, 29, 615-619.	1.7	12
333	Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity. Journal of Biological Chemistry, 2021, 297, 101132.	1.6	4

#	Article	IF	Citations
334	Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or Death. Clinical Gastroenterology and Hepatology, 2021, 19, 2182-2191.e7.	2.4	28
335	Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients. International Journal of Infectious Diseases, 2021, 111, 211-218.	1.5	29
336	Von Willebrand factor: A key glycoprotein involved in thrombo-inflammatory complications of COVID-19. Chemico-Biological Interactions, 2021, 348, 109657.	1.7	12
337	Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role. Trends in Microbiology, 2021, 29, 894-907.	3.5	53
338	Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity. International Immunopharmacology, 2021, 99, 107995.	1.7	27
339	Research progress on the utilisation of embedding technology and suitable delivery systems for improving the bioavailability of nattokinase: A review. Food Structure, 2021, 30, 100219.	2.3	9
340	Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. Microvascular Research, 2021, 138, 104224.	1.1	42
341	Nailfold capillaroscopy: A sensitive method for evaluating microvascular involvement in children with SARS-CoV-2 infection. Microvascular Research, 2021, 138, 104196.	1.1	14
342	Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacological Research, 2021, 173, 105848.	3.1	16
343	Reply. Journal of Infectious Diseases, 2021, 223, 1499-1500.	1.9	0
344	Predicted structural mimicry of spike receptor-binding motifs from highly pathogenic human coronaviruses. Computational and Structural Biotechnology Journal, 2021, 19, 3938-3953.	1.9	25
345	Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study. Annals of Intensive Care, 2021, 11, 14.	2.2	35
346	Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19. International Journal of Biological Sciences, 2021, 17, 897-910.	2.6	30
348	THE KIDNEY AND SKIN DUO IN SARS-COV-2/COVID-19. , 2021, , 1-2.		0
349	Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities. Theranostics, 2021, 11, 8234-8253.	4.6	16
350	Complement activation and coagulopathy - an ominous duo in COVID19. Expert Review of Hematology, 2021, 14, 155-173.	1.0	21
351	Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients. Frontiers in Physiology, 2020, 11, 608788.	1.3	24
352	Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis, 2021, 24, 505-517.	3.7	105

#	Article	IF	Citations
353	Role of Tissue Factor in the Pathogenesis of COVID-19 and the Possible Ways to Inhibit It. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110039.	0.7	21
354	Endothelial cell infection and dysfunction, immune activation in severe COVID-19. Theranostics, 2021, 11, 8076-8091.	4.6	70
355	Proposal of the Definition for COVID-19-Associated Coagulopathy. Journal of Clinical Medicine, 2021, 10, 191.	1.0	83
356	Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clinical Science, 2020, 134, 2987-3006.	1.8	35
357	Hypercoagulopathy in Severe COVID-19: Implications for Acute Care. Thrombosis and Haemostasis, 2020, 120, 1654-1667.	1.8	25
358	A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy. Shock, 2021, 55, 700-716.	1.0	31
359	Role of Von Willebrand Factor after Injury: It May Do More Than We Think. Shock, 2021, 55, 717-722.	1.0	15
371	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVIDâ€19): evidence of acute and sustained endothelial cell activation. British Journal of Haematology, 2021, 192, 714-719.	1.2	92
372	Excess Cerebrovascular Mortality in the United States During the COVID-19 Pandemic. Stroke, 2021, 52, 563-572.	1.0	30
373	ACE2: the molecular doorway to SARS-CoV-2. Cell and Bioscience, 2020, 10, 148.	2.1	82
374	Transcriptional profiling of leukocytes in critically ill COVID19 patients: implications for interferon response and coagulation. Intensive Care Medicine Experimental, 2020, 8, 75.	0.9	37
376	Commonalities Between COVID-19 and Radiation Injury. Radiation Research, 2020, 195, 1-24.	0.7	23
377	Neuropathology of COVID-19 (neuro-COVID): clinicopathological update. Free Neuropathology, 2021, 2, .	2.4	62
379	COVID-19 and vascular disorders (literature review). Regional Blood Circulation and Microcirculation, 2020, 19, 90-98.	0.1	26
380	Update to coagulopathy in COVID-19: Manifestations and management. Cleveland Clinic Journal of Medicine, 2021, , .	0.6	7
381	Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 353-367.	0.2	33
382	Coagulation abnormalities & thromboprophylaxis in COVID-19. Indian Journal of Medical Research, 2021, 153, 606.	0.4	4
383	Endothelial cells are not productively infected by SARSâ€CoVâ€2. Clinical and Translational Immunology, 2021, 10, e1350.	1.7	88

#	Article	IF	Citations
384	Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. Cardiology in Review, 2022, 30, 145-157.	0.6	11
385	The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19. Seminars in Thrombosis and Hemostasis, 2022, 48, 019-030.	1.5	17
386	Changes in pulmonary microcirculation after COVID-19. Pulmonologiya, 2021, 31, 588-597.	0.2	5
387	Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19. Cell Death and Differentiation, 2021, 28, 3199-3213.	5.0	37
388	Plasma <scp>P</scp>â€selectin is an early marker of thromboembolism in <scp>COVID</scp>â€19. American Journal of Hematology, 2021, 96, E468-E471.	2.0	17
389	Are Damaged Lungs Protected from COVID-19? An Interesting Observation. Indian Journal of Radiology and Imaging, 2021, 31, 791-794.	0.3	0
390	Prior Stroke and Age Predict Acute Ischemic Stroke Among Hospitalized COVID-19 Patients: A Derivation and Validation Study. Frontiers in Neurology, 2021, 12, 741044.	1.1	4
391	The relevance of magnesium homeostasis in COVID-19. European Journal of Nutrition, 2022, 61, 625-636.	1.8	42
392	Pulmonary vascular system: A vulnerable target for COVIDâ€19. MedComm, 2021, 2, 531-547.	3.1	10
393	Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19. Life, 2021, 11, 1056.	1.1	23
394	Rapid Detection and Inhibition of SARSâ€CoVâ€2â€Spike Mutationâ€Mediated Microthrombosis. Advanced Science, 2021, 8, e2103266.	5.6	11
395	Role of von Willebrand factor in venous thromboembolic disease. JVS Vascular Science, 2022, 3, 17-29.	0.4	8
396	Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVIDâ€19â€associated thrombopathy. Journal of Thrombosis and Haemostasis, 2022, 20, 17-31.	1.9	45
397	Neurotropism of SARS-CoV-2 and neurological diseases of the central nervous system in COVID-19 patients. Experimental Brain Research, 2022, 240, 9-25.	0.7	38
398	Inflammatory Mediators of Platelet Activation: Focus on Atherosclerosis and COVID-19. International Journal of Molecular Sciences, 2021, 22, 11170.	1.8	34
400	Postmortem Documentation of SARS-CoV-2 in Utero and Postpartum Transmission, through Amniotic Fluid, Placental, and Pulmonary Tissue RT-PCR. Applied Sciences (Switzerland), 2021, 11, 9505.	1.3	5
401	A review on protective roles and potential mechanisms of metformin in diabetic patients diagnosed with COVID-19. Metabolism Open, 2021, 12, 100137.	1.4	5
402	Clinical Features and Management of COVID-19 Associated Hypercoagulability. Cardiac Electrophysiology Clinics, 2021, 14, 41-52.	0.7	2

#	Article	IF	Citations
403	Single-photon emission tomography of the lungs in the diagnosis of coagulopathyin patients in the postcovid period. Meditsinskiy Sovet, 2021, , 110-117.	0.1	0
404	Unconventional CD147â€dependent platelet activation elicited by SARSâ€CoVâ€2 in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2022, 20, 434-448.	1.9	50
405	The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19. SeÄenovskij Vestnik, 2020, 11, 29-39.	0.3	0
406	Are Aspirin and Apixaban Sufficient to Prevent Immunothrombosis in COVID-19?. SSRN Electronic Journal, 0, , .	0.4	1
407	Elevated Plasma Levels of ICAM1 Predict Mortality in COVID-19 and Sepsis Patients with Liver Cirrhosis. SSRN Electronic Journal, 0, , .	0.4	0
408	Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Frontiers in Immunology, 2021, 12, 773352.	2.2	105
409	Complex Pathophysiological Mechanisms and the Propose of the Three-Dimensional Schedule For Future COVID-19 Treatment. Frontiers in Immunology, 2021, 12, 716940.	2.2	1
410	Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. Current Opinion in Nephrology and Hypertension, 2022, 31, 36-46.	1.0	11
411	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. International Journal of Molecular Sciences, 2021, 22, 12081.	1.8	21
412	Platelet extracellular vesicles in COVID-19: Potential markers and makers. Journal of Leukocyte Biology, 2021, 111, 63-74.	1.5	26
413	SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism. Viruses, 2021, 13, 2209.	1.5	36
414	Thrombotic storm, hemostasis disorders and thromboinflammation in COVID-19. Obstetrics, Gynecology and Reproduction, 2021, 15, 499-514.	0.2	8
416	High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis. Clinical and Experimental Medicine, 2022, 22, 347-357.	1.9	23
417	Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients. Thrombosis Journal, 2021, 19, 79.	0.9	8
421	Von Willebrand factor. Clinical Medicine, 2020, 20, e279-e279.	0.8	2
422	Neutrophil extracellular traps (NETs): the role of inflammation and coagulation in COVID-19. American Journal of Translational Research (discontinued), 2021, 13, 8575-8588.	0.0	1
423	A Splenic Infarction Related to Parainfluenza Infection in a Patient with AML: Lessons for COVID-19. Acta Biomedica, 2021, 92, e2021256.	0.2	0
424	COVID Cardiovascular Illness. , 2021, , 99-109.		0

#	Article	IF	Citations
425	Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. Journal of Molecular and Cellular Cardiology, 2022, 164, 69-82.	0.9	34
426	Emerging Knowledge of the Neurobiology of COVID-19. Psychiatric Clinics of North America, 2022, 45, 29-43.	0.7	11
427	Spike protein multiorgan tropism suppressed by antibodies targeting SARS-CoV-2. Communications Biology, 2021, 4, 1318.	2.0	8
428	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. Cardiology Discovery, 2021, 1, 233-258.	0.6	6
429	SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities. Cytokine and Growth Factor Reviews, 2022, 63, 44-57.	3.2	41
430	A Simple Scoring Model Predicting the Outcome of COVID-19 Patients: Tanta COVID score. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, .	0.6	0
431	Diagnostic Approaches for COVID-19 and Its Associated Complications. Diagnostics, 2021, 11, 2071.	1.3	7
432	Corona Virus Disease 2019 (COVID-19) as a System-Level Infectious Disease With Distinct Sex Disparities. Frontiers in Immunology, 2021, 12, 778913.	2.2	5
433	Low Brachial Artery Flow-Mediated Dilation Predicts Worse Prognosis in Hospitalized Patients with COVID-19. Journal of Clinical Medicine, 2021, 10, 5456.	1.0	16
434	COVID-19, Pre-Eclampsia, and Complement System. Frontiers in Immunology, 2021, 12, 775168.	2.2	19
435	Covidâ€19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. Hepatology Communications, 2022, 6, 255-269.	2.0	41
436	Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 324-329.	2.5	16
437	MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 Severity. Journal of Personalized Medicine, 2021, 11, 1166.	1.1	7
438	Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research. Current Pain and Headache Reports, 2021, 25, 73.	1.3	30
439	TEGÂ®, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy. Journal of Clinical Medicine, 2021, 10, 5381.	1.0	30
440	COVID-19: The Impact on Cardiovascular System. Biomedicines, 2021, 9, 1691.	1.4	5
441	Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality. , 2021, 3, e0588.		11
442	A Composite study of Coagulation Milieu in Covid-19: Experience from a Tertiary Care Centre from India. Cardiovascular & Hematological Disorders Drug Targets, 2021, 21, .	0.2	0

#	Article	IF	Citations
443	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Advances, 2022, 6, 866-881.	2.5	31
444	Syndecan-1, an indicator of endothelial glycocalyx degradation, predicts outcome of patients admitted to an ICU with COVID-19. Molecular Medicine, 2021, 27, 151.	1.9	36
445	Biomarkers of thromboinflammation correlate to COVID-19 infection and admission status in emergency department patients. Thrombosis Update, 2021, 5, 100090.	0.4	2
446	Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins. PLoS Pathogens, 2021, 17, e1010118.	2.1	30
447	Hemostatic System (Fibrinogen Level, D-Dimer, and FDP) in Severe and Non-Severe Patients With COVID-19: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110109.	0.7	14
448	Galectinâ€9 activates platelet ITAM receptors glycoprotein VI and Câ€type lectinâ€like receptorâ€2. Journal of Thrombosis and Haemostasis, 2022, 20, 936-950.	1.9	7
449	Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register. Internal and Emergency Medicine, 2022, , 1.	1.0	11
450	Continuation of therapeutic anticoagulation before and during hospitalization is associated with reduced mortality in COVID-19 ICU patients. Journal of Lung, Pulmonary & Respiratory Research, 2021, 8, 120-130.	0.3	0
451	COVID-19 infection-associated coagulopathy: Pathophysiology and clinical implications. Interventional Neuroradiology, 2021, 27, 6-12.	0.7	3
452	Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19. JACC Basic To Translational Science, 2021, 6, 935-945.	1.9	23
454	The cGASâ€“STING pathway drives type I IFN immunopathology in COVID-19. Nature, 2022, 603, 145-151.	13.7	272
455	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	6.1	180
456	Endotheliopathy Is Associated With a 24-Hour Fibrinolysis Phenotype Described by Low TEG Lysis and High d-Dimer After Trauma. Annals of Surgery Open, 2022, 3, e116.	0.7	6
457	Associations between the von Willebrand Factorâ€”ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality. Thrombosis and Haemostasis, 2022, 122, 240-256.	1.8	15
458	Cumulative Evidence for the Association of Thrombosis and the Prognosis of COVID-19: Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 819318.	1.1	12
459	Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations. Cells, 2022, 11, 306.	1.8	15
460	Coagulation Studies Are Not Predictive of Hematological Complications of COVID-19 Infection. TH Open, 2022, 06, e1-e9.	0.7	2
461	Multiplatform Analyses Reveal Distinct Drivers of Systemic Pathogenesis in Adult Versus Pediatric COVID-19. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
462	From heart to muscle: pathophysiological mechanisms underlying long-term physical sequelae from SARS-CoV-2 infection. Journal of Applied Physiology, 2022, 132, 581-592.	1.2	26
463	Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation. Critical Care Medicine, 2022, Publish Ahead of Print, .	0.4	33
464	Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H87-H93.	1.5	19
465	Vasculopathy in COVID-19. Blood, 2022, 140, 222-235.	0.6	63
466	Features of the novel coronavirus infection in cancer patients. Obstetrics, Gynecology and Reproduction, 2022, 15, 726-737.	0.2	1
467	Hypertensive patients features of the microcirculation type after new coronavirus infection of COVID-19. Regional Blood Circulation and Microcirculation, 2022, 20, 45-51.	0.1	1
468	Evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID-19 patients. Clinical and Experimental Medicine, 2022, 22, 567-575.	1.9	22
469	Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210743.	0.7	12
470	Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert Opinion on Therapeutic Targets, 2022, 26, 13-28.	1.5	5
471	Genetic prediction of ICU hospitalization and mortality in COVIDâ€19 patients using artificial neural networks. Journal of Cellular and Molecular Medicine, 2022, 26, 1445-1455.	1.6	45
472	Revisiting Metchnikoff's work in light of the COVID-19 pandemic. Innate Immunity, 2022, 28, 57-66.	1.1	1
473	ÐŸÐ°Ñ‚Ð³ÐµÐ½ÐµÐ·Ð¸Ñ‡Ð½Ñ– Ð¼ÐµÑ…Ð°Ð½Ñ–Ð·Ð¼Ð¸ Ð³ÐµÐ½ÐµÑ€Ð°Ð»Ñ–Ð·Ð¾Ð²Ð°Ð½Ð¾Ñ— Ð²Ñ–Ñ€ÑƒÑ		
474	Possibility as role of ginseng and ginsenosides on inhibiting the heart disease of COVID-19: A systematic review. Journal of Ginseng Research, 2022, 46, 321-330.	3.0	14
475	SARS-CoV-2 membrane protein causes the mitochondrial apoptosis and pulmonary edema via targeting BOK. Cell Death and Differentiation, 2022, 29, 1395-1408.	5.0	39
476	Angiotensin-Converting Enzyme Genotypeâ€“Specific Immune Response Contributes to the Susceptibility of COVID-19: A Nested Caseâ€“Control Study. Frontiers in Pharmacology, 2021, 12, 759587.	1.6	5
477	Single photon emission computed tomography of the lungs in patients with a new coronavirus infection. Diagnostic Radiology and Radiotherapy, 2022, 12, 65-73.	0.0	1
478	Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs. EBioMedicine, 2022, 75, 103812.	2.7	39
479	Inflammation-Induced Coagulopathy Substantially Differs Between COVID-19 and Septic Shock: A Prospective Observational Study. Frontiers in Medicine, 2021, 8, 780750.	1.2	9

#	Article	IF	Citations
480	OUP accepted manuscript. Laboratory Medicine, 2022, , .	0.8	1
481	Neutrophils predominate the immune signature of cerebral thrombi in COVID-19 stroke patients. Acta Neuropathologica Communications, 2022, 10, 14.	2.4	27
482	IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. Annual Review of Immunology, 2022, 40, 323-348.	9.5	50
483	Of mice and human-specific long noncoding RNAs. Mammalian Genome, 2022, 33, 281-292.	1.0	6
484	Renal consequences of the novel coronavirus disease 2019 (COVID-19) and hydrogen sulfide as a potential therapy. Nitric Oxide - Biology and Chemistry, 2022, 120, 16-25.	1.2	6
485	COVID-19 Coagulopathy: From Pathogenesis to Treatment. Acta Haematologica, 2022, 145, 282-296.	0.7	19
486	Transcriptional landscape of circulating platelets from patients with COVID-19 reveals key subnetworks and regulators underlying SARS-CoV-2 infection: implications for immunothrombosis. Cell and Bioscience, 2022, 12, 15.	2.1	8
488	Thrombosis pathways in COVIDâ€19 versus influenzaâ€associated ARDS: a targeted proteomics approach. Journal of Thrombosis and Haemostasis, 2022, , .	1.9	4
489	Emerging Role of Platelet-Endothelium Interactions in the Pathogenesis of Severe SARS-CoV-2 Infection-Associated Myocardial Injury. Frontiers in Immunology, 2022, 13, 776861.	2.2	12
490	The state of complement in COVID-19. Nature Reviews Immunology, 2022, 22, 77-84.	10.6	159
491	Risk Factors of Severe Disease and Methods for Clinical Outcome Prediction in Patients with COVID-19 (Review). Obshchaya Reanimatologiya, 2022, 18, 31-38.	0.2	5
492	SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research. World Journal of Cardiovascular Diseases, 2022, 12, 168-190.	0.0	0
493	Anticoagulants and corticosteroids in COVID-19: What do we know so far?. Srpski Medicinski Äasopis Lekarske Komore, 2022, 3, 62-74.	0.1	1
495	Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients. Frontiers in Immunology, 2022, 13, 815833.	2.2	11
496	Prevalence of Deep Venous Thrombosis in Abdominoplasty Patients after COVID-19 Convalescence: An Alarming Flag. Plastic and Reconstructive Surgery - Global Open, 2022, 10, e4196.	0.3	3
497	Research into Morphofunctional Characteristics of Erythrocytes in COVID-19 Patients. Biomedicines, 2022, 10, 553.	1.4	3
498	A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochemical Journal, 2022, 479, 537-559.	1.7	126
499	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduction and Targeted Therapy, 2022, 7, 57.	7.1	34

#	Article	IF	Citations
500	Investigation of an alternative to direct anticoagulants in COVID-19 patients. Hirurg, 2022, , 66-80.	0.0	0
501	A case report of COVID-19-associated acute hand ischaemia in a young professional volleyball player. European Heart Journal - Case Reports, 2022, 6, ytac099.	0.3	2
502	COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. Frontiers in Cell and Developmental Biology, 2022, 10, 824851.	1.8	51
503	Major coagulation disorders and parameters in COVID-19 patients. European Journal of Medical Research, 2022, 27, 25.	0.9	32
504	More autopsy studies are needed to understand the pathogenesis of severe COVID-19. Nature Medicine, 2022, 28, 427-428.	15.2	11
505	On the Origin of Neutrophil Extracellular Traps in COVID-19. Frontiers in Immunology, 2022, 13, 821007.	2.2	15
506	Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation. International Journal of Molecular Sciences, 2022, 23, 3868.	1.8	50
507	Meta-Analysis and Systematic Review of Coagulation Disbalances in COVID-19: 41 Studies and 17,601 Patients. Frontiers in Cardiovascular Medicine, 2022, 9, 794092.	1.1	18
508	Endothelial Transcytosis in Acute Lung Injury: Emerging Mechanisms and Therapeutic Approaches. Frontiers in Physiology, 2022, 13, 828093.	1.3	10
509	Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine, 2022, 77, 103893.	2.7	48
510	Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review. Frontiers in Immunology, 2022, 13, 835104.	2.2	28
511	Association between COVID-19 Diagnosis and Coronary Artery Thrombosis: A Narrative Review. Biomedicines, 2022, 10, 702.	1.4	15
512	SARSâ€CoVâ€2 infection induces soluble platelet activation markers and PAIâ€1 in the early moderate stage of COVIDâ€19. International Journal of Laboratory Hematology, 2022, 44, 712-721.	0.7	28
513	Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. Journal of Microbiology, 2022, 60, 308-320.	1.3	6
514	Endothelial glycocalyx damage in patients with severe COVID-19 on mechanical ventilation â€“ A prospective observational pilot study. Clinical Hemorheology and Microcirculation, 2022, 81, 205-219.	0.9	11
515	Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. International Journal of Molecular Sciences, 2022, 23, 3338.	1.8	11
516	When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation of the DGC/BDC and the DGAI/BDA. Langenbeck's Archives of Surgery, 2022, 407, 1315-1332.	0.8	5
517	Levels of endothelin-1 and high molecular weight kininogen in blood of breast cancer patients after SARS-coV-2 infection. Siberian Journal of Oncology, 2022, 21, 29-36.	0.1	0

#	Article	IF	Citations
518	Relationship Between Endothelial and Angiogenesis Biomarkers Envisage Mortality in a Prospective Cohort of COVID-19 Patients Requiring Respiratory Support. Frontiers in Medicine, 2022, 9, 826218.	1.2	17
519	Distinct etiologies of high-sensitivity troponin T elevation predict different mortality risks for patients hospitalized with COVID-19. International Journal of Cardiology, 2022, 351, 118-125.	0.8	10
520	Impaired Endothelial Function in Convalescent Phase of COVID-19: A 3 Month Follow Up Observational Prospective Study. Journal of Clinical Medicine, 2022, 11, 1774.	1.0	15
521	Heparan sulfate mimetic fucoidan restores the endothelial glycocalyx and protects against dysfunction induced by serum of COVID-19 patients in the intensive care unit. ERJ Open Research, 2022, 8, 00652-2021.	1.1	14
522	The pathological maelstrom of COVID-19 and cardiovascular disease. , 2022, 1, 200-210.		14
523	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. Frontiers in Microbiology, 2022, 13, 860931.	1.5	15
524	Aspirin in COVID-19: Pros and Cons. Frontiers in Pharmacology, 2022, 13, 849628.	1.6	10
525	Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy. A Non-systematic Review of Clinical Presentation, Potential Effects of Physiological Adaptations in Pregnancy, and Placental Vascular Alterations. Frontiers in Physiology, 2022, 13, 785274.	1.3	7
526	Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures. TH Open, 2022, 06, e194-e212.	0.7	12
527	Endothelial Dysfunction in SARS-CoV-2 Infection. Biomedicines, 2022, 10, 654.	1.4	6
528	Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19. Blood Advances, 2022, 6, 3367-3377.	2.5	17
529	COVID-19 and thrombosis: The role of hemodynamics. Thrombosis Research, 2022, 212, 51-57.	0.8	28
530	The incidence and clinical impact of thrombotic events in hospitalised Coronavirus disease 2019 illness. International Angiology, 2022, , .	0.4	0
531	Minimal Change Disease Is Associated With Endothelial Glycocalyx Degradation and Endothelial Activation. Kidney International Reports, 2022, 7, 797-809.	0.4	11
532	COVID-19 therapeutics: Challenges and directions for the future. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2119893119.	3.3	92
533	Characterization of Altered Gene Expression and Histone Methylation in Peripheral Blood Mononuclear Cells Regulating Inflammation in COVID-19 Patients. Journal of Immunology, 2022, 208, 1968-1977.	0.4	8
534	Persistent Lung Injury and Prothrombotic State in Long COVID. Frontiers in Immunology, 2022, 13, 862522.	2.2	15
535	The Importance of Nutraceuticals in COVID-19: Whatâ€™s the Role of Resveratrol?. Molecules, 2022, 27, 2376.	1.7	16

#	Article	IF	Citations
536	Effect of Antiplatelet Therapy on Survival and Organ Supportâ€“Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	3.8	83
537	Cardiovascular signatures of COVID-19 predict mortality and identify barrier stabilizing therapies. EBioMedicine, 2022, 78, 103982.	2.7	17
538	Associations between hemostatic markers and mortality in COVID-19 â€“ Compounding effects of D-dimer, antithrombin and PAP complex. Thrombosis Research, 2022, 213, 97-104.	0.8	8
539	Long-term outcomes of pediatric infections: from traditional infectious diseases toÂlongÂCovid. Future Microbiology, 2022, 17, 551-571.	1.0	62
540	Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. Journal of Molecular and Cellular Cardiology, 2022, 167, 92-96.	0.9	19
541	The effect of prostacyclin infusion on markers of endothelial activation and damage in mechanically ventilated patients with SARS-CoV-2 infection. Journal of Critical Care, 2022, 69, 154010.	1.0	5
542	The endothelial glycocalyx in critical illness: A pediatric perspective. Matrix Biology Plus, 2022, 14, 100106.	1.9	9
544	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infectious Diseases, 2022, 9, ofab640.	0.4	56
545	Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 disease. Journal of Thrombosis and Thrombolysis, 2021, , 1.	1.0	6
547	The Pathobiological Basis for Thrombotic Complications in COVID-19: a Review of the Literature. Current Pathobiology Reports, 2021, 9, 107-117.	1.6	6
548	Fundamentals in Covid-19-Associated Thrombosis: Molecular and Cellular Aspects. Frontiers in Cardiovascular Medicine, 2021, 8, 785738.	1.1	20
549	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. Journal of Clinical Medicine, 2021, 10, 5815.	1.0	6
550	Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies. International Journal of Environmental Research and Public Health, 2021, 18, 12944.	1.2	19
551	Post-COVID syndrome: prevalence, organ pathogenesis and routes of correction. A systematic review. Kuban Scientific Medical Bulletin, 2021, 28, 90-116.	0.1	4
552	Metabolic Influences Modulating Erythrocyte Deformability and Eryptosis. Metabolites, 2022, 12, 4.	1.3	26
553	HEMOCOVID-19 study: an international clinical study to evaluate microvascular and endothelial impairments in severe COVID-19 patients using near-infrared spectroscopy. , 2021, , .		0
554	Prothrombotic Phenotype in COVID-19: Focus on Platelets. International Journal of Molecular Sciences, 2021, 22, 13638.	1.8	21
555	COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Critical Reviews in Oncology/Hematology, 2021, 168, 103529.	2.0	22

#	Article	IF	Citations
556	Six-month longitudinal tracking of arterial stiffness and blood pressure in young adults following SARS-CoV-2 infection. Journal of Applied Physiology, 2022, 132, 1297-1309.	1.2	17
557	SERPINE1 rs6092 Variant Is Related to Plasma Coagulation Proteins in Patients with Severe COVID-19 from a Tertiary Care Hospital. Biology, 2022, 11, 595.	1.3	5
558	Reply. Arthritis and Rheumatology, 2022, 74, 1603-1604.	2.9	0
559	Characterization of COVID-19-associated cardiac injury: evidence for a multifactorial disease in an autopsy cohort. Laboratory Investigation, 2022, 102, 814-825.	1.7	19
560	Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke. Circulation Research, 2022, 130, 1167-1186.	2.0	74
561	COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. Seminars in Immunopathology, 2022, 44, 375-390.	2.8	15
562	Characterization of coagulopathy and outcomes in cancer patients with severe <scp>COVID</scp> â€19 illness: Longitudinal changes in hospitalized cancer patients. Cancer Medicine, 2022, 11, 3771-3785.	1.3	3
563	Implications of microvascular dysfunction and nitric oxide mediated inflammation in severe COVID-19 infection. American Journal of the Medical Sciences, 2022, 364, 251-256.	0.4	2
564	Discrepancy between Mild Muscle Pathology and Severe Muscular Compromise in COVID-19 Suggests Nonviral Etiologies. Journal of Neuropathology and Experimental Neurology, 2021, 80, 1088-1090.	0.9	0
565	Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (<scp>COVID</scp>â€19) patients. International Journal of Laboratory Hematology, 2022, 44, 817-822.	0.7	3
567	Association between periodontal disease and the risk of COVID-19 complications and mortality: A systematic review. Journal of International Society of Preventive and Community Dentistry, 2021, 11, 626.	0.4	6
568	Risk factors and severity of functional impairment in long COVID: a single-center experience in Croatia.. Croatian Medical Journal, 2022, 63, 27-35.	0.2	0
569	Thromboembolic Events in Deceased Patients with Proven SARS-CoV-2 Infection: Frequency, Characteristics and Risk Factors. SSRN Electronic Journal, 0, , .	0.4	0
570	Transcriptomic Analysis of the Peripheral Immune Cell of SARS-CoV-2 Infected Patients for Bridging the Genotype-Phenotype Gap and Drug Prediction: A Precision Medicine Approach. SSRN Electronic Journal, 0, , .	0.4	0
571	The Cardiovascular Manifestations of COVID-19. Cardiology Clinics, 2022, 40, 277-285.	0.9	5
572	SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review. Biomedicines, 2022, 10, 962.	1.4	6
573	Assessment and Monitoring of Coagulation in Patients with COVID-19: A Review of Current Literature. Hamostaseologie, 2022, 42, 409-419.	0.9	3
574	Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial. Pediatrics, 2022, 150, .	1.0	19

#	Article	IF	Citations
575	Weighted Gene Co-Expression Network Analysis to Identify Potential Biological Processes and Key Genes in COVID-19-Related Stroke. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14.	1.9	9
576	Venous Thromboembolism and COVID-19â€"an Epidemiological Perspective. Indian Journal of Surgery, 2022, , 1-8.	0.2	0
577	The Genetic Risk for COVID-19 Severity Is Associated With Defective Immune Responses. Frontiers in Immunology, 2022, 13, .	2.2	4
578	Early Renal-Replacement Therapy May Reduce the All-Cause Mortality of Severe COVID-19: An Observational Cohort Study. Blood Purification, 2022, 51, 1006-1014.	0.9	3
579	COVID-Associated Avascular Necrosis of the Maxillaâ€"A Rare, New Side Effect of COVID-19. Journal of Oral and Maxillofacial Surgery, 2022, 80, 1254-1259.	0.5	7
580	Anticoagulant Treatment in Severe ARDS COVID-19 Patients. Journal of Clinical Medicine, 2022, 11, 2695.	1.0	4
581	The effect of coronavirus disease 2019 pneumonia on myocardial ischemia detected by single-photon emission computed tomography myocardial perfusion imaging. Nuclear Medicine Communications, 2022, Publish Ahead of Print, .	0.5	1
582	Obstructive Sleep Apnea as a Risk Factor for COVID-19 Severityâ€"The Gut Microbiome as a Common Player Mediating Systemic Inflammation via Gut Barrier Dysfunction. Cells, 2022, 11, 1569.	1.8	8
583	von Willebrand disease and von Willebrand factor. Haemophilia, 2022, 28, 11-17.	1.0	3
584	ENDOTHELIAL BIOMARKERS IN PATIENTS RECOVERED FROM COVID-19 ONE YEAR AFTER HOSPITAL DISCHARGE: A CROSS-SECTIONAL STUDY. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022033.	0.5	10
585	Post-COVID-19 hematologic complications: a systematic review. Expert Review of Hematology, 2022, 15, 539-546.	1.0	6
586	Markers of endothelial cell activation are associated with the severity of pulmonary disease in COVID-19. PLoS ONE, 2022, 17, e0268296.	1.1	12
587	Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis. Diagnostics, 2022, 12, 1261.	1.3	1
588	Methods to evaluate vascular function: a crucial approach towards predictive, preventive, and personalised medicine. EPMA Journal, 2022, 13, 209-235.	3.3	10
589	Morphofunctional Characteristics of Erythrocytes and Blood Erythropoietin Level in Patients as Predictors of Severe Course of COVID-19. Bulletin of Experimental Biology and Medicine, 0, , .	0.3	2
591	The Endothelium and COVID-19: An Increasingly Clear Link Brief Title: Endotheliopathy in COVID-19. International Journal of Molecular Sciences, 2022, 23, 6196.	1.8	16
592	Resistance Training before, during, and after COVID-19 Infection: What Have We Learned So Far?. International Journal of Environmental Research and Public Health, 2022, 19, 6323.	1.2	3
593	Premortem Skin Biopsy Assessing Microthrombi, Interferon Type I Antiviral and Regulatory Proteins, and Complement Deposition Correlates with Coronavirus Disease 2019 Clinical Stage. American Journal of Pathology, 2022, 192, 1282-1294.	1.9	13

#	Article	IF	Citations
594	Introduction to a review series on COVID-19 and the hematologist. Blood, 2022, 140, 163-164.	0.6	1
596	Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register. TH Open, 2022, 06, e251-e256.	0.7	2
597	Identification of bronchoalveolar and blood immune-inflammatory biomarker signature associated with poor 28-day outcome in critically ill COVID-19 patients. Scientific Reports, 2022, 12, .	1.6	12
598	Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
599	Coronavirus disease (COVID-19) Associated mucormycosis (CAM). Journal of Cellular Biotechnology, 2022, , 1-6.	0.1	0
600	Angiopoietin-2 Inhibition of Thrombomodulin-Mediated Anticoagulationâ€"A Novel Mechanism That May Contribute to Hypercoagulation in Critically Ill COVID-19 Patients. Biomedicines, 2022, 10, 1333.	1.4	11
601	Vascular Endothelial Glycocalyx Damage and Potential Targeted Therapy in COVID-19. Cells, 2022, 11, 1972.	1.8	17
602	Novel aspects of sepsis pathophysiology: NETs, plasma glycoproteins, endotheliopathy and COVID-19. Journal of Pharmacological Sciences, 2022, 150, 9-20.	1.1	7
603	COVIDâ€19 coagulopathy â€“ what should we treat?. Experimental Physiology, 2022, 107, 749-758.	0.9	8
604	The Role of Host-Cellular Responses in COVID-19 Endothelial Dysfunction. Current Drug Targets, 2022, 23, .	1.0	1
605	Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature. Cardiovascular Research, 2022, 118, 3085-3096.	1.8	17
606	Association of obesity with COVID-19 diseases severity and mortality: A meta-analysis of studies. Obesity Medicine, 2022, 33, 100431.	0.5	5
607	COVID Coagulopathy and Thrombosis: A Systematic Review. Touch Reviews in Oncology & Haematology, 2022, 18, 78.	0.1	2
608	Glycocalyx heparan sulfate cleavage promotes endothelial cell angiopoietin-2 expression by impairing shear stressâ€"related AMPK/FoxO1 signaling. JCI Insight, 2022, 7, .	2.3	9
609	Thromboprophylaxis in people hospitalized with <scp>COVID</scp> â€19: Assessing intermediate or standard doses in a retrospective cohort study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	0
610	Paroxysmal Finger Hematomaâ€"A Probable Vascular Disorder in Post-COVID-19 Condition: Two Clinical Case Presentations. Medicina (Lithuania), 2022, 58, 915.	0.8	1
611	Dengue and COVID-19: two sides of the same coin. Journal of Biomedical Science, 2022, 29, .	2.6	16
612	Proteomic and Metabolomic Characterization of SARS-CoV-2-Infected Cynomolgus Macaque at Early Stage. Frontiers in Immunology, 0, 13, .	2.2	3

#	Article	IF	Citations
613	The suboptimal fibrinolytic response in COVIDâ€19 is dictated by high PAIâ€1. Journal of Thrombosis and Haemostasis, 2022, 20, 2394-2406.	1.9	30
614	Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors. Thrombosis Research, 2022, 216, 120-124.	0.8	7
615	The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges. Thrombosis Update, 2022, 8, 100117.	0.4	1
616	Downregulation of thrombomodulin-thrombin-activated protein C pathway as a mechanism for SARS-CoV-2 induced endotheliopathy and microvascular thrombosis. Thrombosis Update, 2022, 8, 100116.	0.4	0
617	Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation. International Immunopharmacology, 2022, 110, 109040.	1.7	4
618	Trend of fluctuations of antithrombin in plasma of patients with COVID-19: a meta-analysis and systematic review. Expert Review of Hematology, 0, , .	1.0	3
619	The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?. Croatian Medical Journal, 2022, 63, 287-294.	0.2	1
620	Complement contributions to COVID-19. Current Opinion in Hematology, 2022, 29, 259-265.	1.2	7
621	Dysregulation of immunity in COVID-19 and SLE. Inflammopharmacology, 2022, 30, 1517-1531.	1.9	6
622	The role of platelets, neutrophils and endothelium in COVID-19 infection. Expert Review of Hematology, 2022, 15, 727-745.	1.0	7
623	Fibrinogen, Fibrin, and Fibrin Degradation Products in COVID-19. Current Drug Targets, 2022, 23, 1593-1602.	1.0	6
624	Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine. EPMA Journal, 2022, 13, 407-431.	3.3	5
625	Peculiarities of hemostasis in patients with COVID-19. Terapevticheskii Arkhiv, 2022, 94, 876-883.	0.2	0
626	Impact of innate immunity, endothelial damage, and metabolic biomarkers on COVID-19 severity and mortality. Open Forum Infectious Diseases, 0, , .	0.4	2
627	The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
628	Understanding COVID-19-associated coagulopathy. Nature Reviews Immunology, 2022, 22, 639-649.	10.6	137
629	Increased Lung Immune Metabolic Activity in COVID-19 Survivors. Clinical Nuclear Medicine, 2022, 47, 1019-1025.	0.7	4
630	Lower brachial artery flow-mediated dilation is associated with a worse prognosis and more lung parenchymal involvement in Covid-19: Prospective observational study. Medicine (United States), 2022, 101, e30001.	0.4	3

#	Article	IF	Citations
631	Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use. European Journal of Clinical Pharmacology, 2022, 78, 1601-1611.	0.8	10
632	Case report: Nocardial brain abscess in a persistently SARS-CoV-2 PCR positive patient with systemic lupus erythematosus. Frontiers in Medicine, 0, 9, .	1.2	2
633	COVID-19-specific transcriptomic signature detectable in blood across multiple cohorts. Frontiers in Genetics, 0, 13, .	1.1	4
634	Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis. Thrombosis Research, 2022, 218, 83-98.	0.8	9
635	SARS-CoV-2 and COVID-19: A Narrative Review. , 0, 79, .		9
636	Long Covid: where we stand and challenges ahead. Cell Death and Differentiation, 0, , .	5.0	34
637	Postoperative outcomes of cardio-thoracic surgery in post-COVID versus non-COVID patients - Single-center experience. Journal of the Practice of Cardiovascular Sciences, 2022, 8, 22.	0.0	0
638	Coagulation Disorders and Management. , 2022, , 235-247.		0
639	Editorial commentary on the article â€œNeurological Disorders Seen During Second Wave of SARS-CoV-2 Pandemic from Two Tertiary Care Centers in Central and Southern Keralaâ€• Annals of Indian Academy of Neurology, 2022, 25, 185.	0.2	0
640	Pathophysiology of Coagulopathy in COVID-19. , 2022, , 223-234.		0
641	Biochemical and Anthropometric Nutritional Assessment in Children Infected with COVID-19: A Cross-sectional Study. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 1818-1826.	0.1	2
642	The potential role of ischaemiaâ€“reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Biochemical Journal, 2022, 479, 1653-1708.	1.7	27
643	Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives. Cell Communication and Signaling, 2022, 20, .	2.7	10
644	Vascular Aging and COVID-19. Angiology, 2023, 74, 308-316.	0.8	5
645	Bioinformatics and systems biology approach to identify the pathogenetic link of Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Immunology, 0, 13, .	2.2	9
646	Renal, cardiac, neurological, cutaneous and coagulopathic long-term manifestations of COVID-19 after recovery; A review. Epidemiology and Infection, 2022, 150, .	1.0	3
647	Lung Ultrasound Findings and Endothelial Perturbation in a COVID-19 Low-Intensity Care Unit. Journal of Clinical Medicine, 2022, 11, 5425.	1.0	1
648	Low Cardiorespiratory Fitness Post-COVID-19: A Narrative Review. Sports Medicine, 2023, 53, 51-74.	3.1	33

#	Article	IF	Citations
649	Ischemic stroke in a pediatric patient: complication of the course of COVID-19 (clinical case and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7	0.1	0
650	SARS-CoV-2 infection and diabetes: Pathophysiological mechanism of multi-system organ failure. World Journal of Virology, 0, 11, 252-274.	1.3	2
651	The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors. Frontiers in Immunology, 0, 13, .	2.2	5
652	Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. Frontiers in Medicine, 0, 9, .	1.2	10
653	SARS-CoV-2 Spike protein promotes vWF secretion and thrombosis via endothelial cytoskeleton-associated protein 4 (CKAP4). Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	5
654	Recommendation: Treatment of clinical long COVID encephalopathies with nasal administered mesenchymal stromal cell extracellular vesicles. Frontiers in Nanotechnology, 0, 4, .	2.4	3
655	Newâ€'onset neuropsychiatric sequelae and â€˜longâ€'COVIDâ€™ syndrome (Review). Experimental and Therapeutic Medicine, 2022, 24, .	0.8	7
656	In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211318.	0.7	1
657	Obesity and risk of venous thromboembolic events. Profilakticheskaya Meditsina, 2022, 25, 54.	0.2	0
658	Osteosarcopenia and Long-COVID: a dangerous combination. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211304.	1.2	5
659	Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19. Frontiers in Immunology, 0, 13, .	2.2	5
660	Nucleic Acid Delivery to the Vascular Endothelium. Molecular Pharmaceutics, 2022, 19, 4466-4486.	2.3	2
662	Acute Myocardial Infarction Complicating Coronavirus Infection (Case Report). Obshchaya Reanimatologiya, 2022, 18, 18-23.	0.2	2
663	Effect of stimulated platelets in COVID-19 thrombosis: Role of alpha7 nicotinic acetylcholine receptor. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
664	Therapeutic advances in COVID-19. Nature Reviews Nephrology, 2023, 19, 38-52.	4.1	67
665	COVID-19 and antiphospholipid antibodies. Best Practice and Research in Clinical Haematology, 2022, 35, 101402.	0.7	12
666	Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism. Molecular Medicine, 2022, 28, .	1.9	35
667	Neutrophil activation and neutrophil extracellular traps (NETs) in COVIDâ€19 ARDS and immunothrombosis. European Journal of Immunology, 2023, 53, .	1.6	26

#	Article	IF	Citations
668	Findings of Abdominal Imaging in Patients with COVID-19 â€“ Part 1: Hollow Organs. Middle East Journal of Digestive Diseases, 2022, 14, 278-286.	0.2	2
669	Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes. The Journal of Critical Care Medicine, 2022, 8, 249-258.	0.3	0
670	Thrombotic storm in coronavirus disease 2019: from underlying mechanisms to its management. Journal of Medical Microbiology, 2022, 71, .	0.7	3
671	Acute Hemorrhagic Leukoencephalitis (AHLE): A Comprehensive Review on Causes, Symptoms, Link with COVID-19, Diagnosis, and Treatment. BioMed Research International, 2022, 2022, 1-9.	0.9	5
672	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. Thrombosis Update, 2022, , 100126.	0.4	0
673	Vascular dysfunction in COVID-19 patients: update on SARS-CoV-2 infection of endothelial cells and the role of long non-coding RNAs. Clinical Science, 2022, 136, 1571-1590.	1.8	7
674	COVID-19 associated liver injury: A general review with special consideration of pregnancy and obstetric outcomes. World Journal of Gastroenterology, 0, 28, 6017-6033.	1.4	1
675	A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury. Kidney International, 2023, 103, 514-528.	2.6	11
676	Biological Assessment of the NO-Dependent Endothelial Function. Molecules, 2022, 27, 7921.	1.7	3
677	Characteristics of subarachnoid hemorrhage associated with COVID-19 infection: A systematic review and descriptive analysis. Journal of Stroke and Cerebrovascular Diseases, 2023, 32, 106904.	0.7	1
678	Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients. Biomedicine and Pharmacotherapy, 2023, 158, 114082.	2.5	6
679	The use of acetylsalicylic acid for prevention of cardiovascular complications in patients undergoing COVID-19. A review of current recommendations. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2022, 15, 656.	0.1	0
680	Non-vitamin K antagonist oral anticoagulants for COVID-19 thrombosis. Journal of Acute Disease, 2022, 11, 212.	0.0	0
681	Gender Differences Associated with Hyper-Inflammatory Conditions in COVID-19 Patients. , 2022, .		0
682	Endothelial injury in severe COVID-19 as a reason for infusion therapy choice. Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya, 2022, , 83.	0.2	2
683	An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. Frontiers in Microbiology, 0, 13, .	1.5	11
684	The potential impact of nanomedicine on COVID-19-induced thrombosis. Nature Nanotechnology, 2023, 18, 11-22.	15.6	6
685	Photoplethysmographic Measurement of Arterial Stiffness in Polish Patients with Long-COVID-19 Syndromeâ€"The Results of a Cross-Sectional Study. Diagnostics, 2022, 12, 3189.	1.3	3

#	Article	IF	Citations
686	Small molecules in the treatment of COVID-19. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	42
687	Molecular Pathogenesis of Fibrosis, Thrombosis and Surfactant Dysfunction in the Lungs of Severe COVID-19 Patients. Biomolecules, 2022, 12, 1845.	1.8	5
690	Thrombosis questions from the inpatient wards. Hematology American Society of Hematology Education Program, 2022, 2022, 481-490.	0.9	1
691	Coagulation potential and the integrated omics of extracellular vesicles from COVID-19 positive patient plasma. Scientific Reports, 2022, 12, .	1.6	9
692	Acute Vascular Injury in COVID-19. Contemporary Cardiology, 2022, , 151-170.	0.0	0
693	Pulmonary Embolism After COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment). Contemporary Cardiology, 2022, , 243-254.	0.0	0
694	Pilot study to evaluate hypercoagulation and inflammation using rotational thromboelastometry and calprotectin in COVID-19 patients. PLoS ONE, 2023, 18, e0269738.	1.1	3
695	COVID-19 and hepatic injury: Diversity and risk assessment. World Journal of Gastroenterology, 0, 29, 425-449.	1.4	5
696	Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis. Journal of Thrombosis and Haemostasis, 2023, 21, 1043-1054.	1.9	4
697	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. PLoS Pathogens, 2023, 19, e1011063.	2.1	7
698	The effects of thrombocytopenia, type 2 diabetes mellitus, and endothelial dysfunction on clinical outcomes in patients with COVID-19. Qatar Medical Journal, 2023, 2023, .	0.2	1
699	Prognostic value of an automated thrombin generation assay in COVID-19 patients entering hospital: A multicentric, prospective observational study. Thrombosis Research, 2023, 222, 85-95.	0.8	0
700	Cardiovascular complications of respiratory viral infections. Sibirskij Å¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 2023, 37, 31-37.	0.1	0
701	Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. Biomedicines, 2023, 11, 338.	1.4	3
702	Dysregulated platelet function in COVID-19 patients. Obstetrics, Gynecology and Reproduction, 2023, 16, 692-705.	0.2	2
703	Thromboprophylaxis in Pregnant Women with COVID-19: An Unsolved Issue. International Journal of Environmental Research and Public Health, 2023, 20, 1949.	1.2	2
704	JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyteâ€“endothelial proadhesive interactions. Journal of Thrombosis and Haemostasis, 2023, 21, 1366-1380.	1.9	8
705	Hemostasis. Lessons From the ICU, 2023, , 233-253.	0.1	0

#	Article	IF	Citations
706	Coagulopathy is Initiated with Endothelial Dysfunction and Disrupted Fibrinolysis in Patients with COVID-19 Disease. Indian Journal of Clinical Biochemistry, 2023, 38, 220-230.	0.9	2
707	Risk of Thrombosis during and after a SARS-CoV-2 Infection: Pathogenesis, Diagnostic Approach, and Management. Hematology Reports, 2023, 15, 225-243.	0.3	5
708	Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. Thrombosis Research, 2023, 225, 47-56.	0.8	2
709	Prognostic markers in patients with COVID-19 requiring intensive care support. Journal of Taibah University Medical Sciences, 2023, 18, 1089-1098.	0.5	0
710	Thromboembolic Events in COVID-19. Contemporary Cardiology, 2022, , 201-216.	0.0	0
711	Reduced circulating BMP9 and pBMP10 in hospitalized COVIDâ€19 patients. Pulmonary Circulation, 2023, 13, .	0.8	2
712	The mechanistic and structural role of von Willebrand factor in endotoxemia-enhanced deep vein thrombosis in mice. Journal of Thrombosis and Haemostasis, 2023, 21, 586-598.	1.9	4
713	Venous thromboembolism in viral diseases: A comprehensive literature review. Health Science Reports, 2023, 6, .	0.6	5
714	The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	17
715	Vitronectin promotes immunothrombotic dysregulation in the venular microvasculature. Frontiers in Immunology, 0, 14, .	2.2	0
716	Humoral immunity and thrombosis in COVID-19. , 2023, , 375-392.		0
717	Impact of COVID-19 on Cardiovascular Disease. Viruses, 2023, 15, 508.	1.5	15
718	Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation. Archives of Cardiovascular Diseases, 2023, 116, 183-191.	0.7	4
719	Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-19. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100085.	1.0	7
721	Pathways of Coagulopathy and Inflammatory Response in SARS-CoV-2 Infection among Type 2 Diabetic Patients. International Journal of Molecular Sciences, 2023, 24, 4319.	1.8	6
722	Interrelation Between the Immune and the Nervous Systems in the Context of Cerebellar Development and Developmental Disorders. Contemporary Clinical Neuroscience, 2023, , 337-362.	0.3	0
723	The Cardiovascular Manifestations of COVID-19. Heart Failure Clinics, 2023, 19, 153-161.	1.0	3
724	COVID-19-Induced Changes in Photoplethysmography. Military Medicine, 0, , .	0.4	3

#	Article	IF	Citations
725	New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF. Frontiers in Immunology, 0, 14, .	2.2	7
726	High Plasma tPAPAI-1C Levels May Be Related to a Poor Prognosis in Patients with Severe or Critical COVID-19: A Single-Center Retrospective Study. Journal of Clinical Medicine, 2023, 12, 2019.	1.0	0
727	COVID-19 and Pulmonary Angiogenesis: The Possible Role of Hypoxia and Hyperinflammation in the Overexpression of Proteins Involved in Alveolar Vascular Dysfunction. Viruses, 2023, 15, 706.	1.5	5
728	Retrospective Study of Thrombosis in Hospitalized Patients with COVID-19 in Rural North Carolina. North Carolina Medical Journal, 2023, 84, .	0.1	0
729	Pneumonia-Induced Inflammation, Resolution and Cardiovascular Disease: Causes, Consequences and Clinical Opportunities. Circulation Research, 2023, 132, 751-774.	2.0	3
730	Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review. Biomedicines, 2023, 11, 929.	1.4	0
731	Intestinal barrier dysfunction as a key driver of severe COVID-19. World Journal of Virology, 0, 12, 68-90.	1.3	4
732	Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19. Journal of Clinical Immunology, 2023, 43, 882-893.	2.0	1
733	COVID-19 and Cardiovascular Diseases: From Cellular Mechanisms to Clinical Manifestations. , 2023, 14, 2071.		4
734	Unraveling the Underlying Molecular Mechanism of â€˜Silent Hypoxiaâ€™ in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway. Journal of Clinical Medicine, 2023, 12, 2445.	1.0	3
735	COVID-19-Associated Coagulopathy: Ascending Aortic Thrombus. Cureus, 2023, , .	0.2	0
736	Multiplatform analyses reveal distinct drivers of systemic pathogenesis in adult versus pediatric severe acute COVID-19. Nature Communications, 2023, 14, .	5.8	9
737	NETosis induction reflects COVID-19 severity and long COVID: insights from a 2-center patient cohort study in Israel. Journal of Thrombosis and Haemostasis, 2023, 21, 2569-2584.	1.9	14
738	Factor VIII: A Dynamic Modulator of Hemostasis and Thrombosis in Trauma. Anesthesia and Analgesia, 2023, 136, 894-904.	1.1	4
739	Evaluation of the interaction between tumor growth factor-Î² and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90Âyears. BMC Infectious Diseases, 2023, 23, .	1.3	3
740	Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement. Annals of Hematology, 2023, 102, 1307-1322.	0.8	7
741	Glutamine Deficiency Promotes Immune and Endothelial Cell Dysfunction in COVID-19. International Journal of Molecular Sciences, 2023, 24, 7593.	1.8	2
742	Damage to endothelial barriers and its contribution to long COVID. Angiogenesis, 2024, 27, 5-22.	3.7	10

#	Article	IF	Citations
779	COVID-19 on Pregnancy Outcomes, Mental Health and Placenta: Focus in Latin America. Advances in Experimental Medicine and Biology, 2023, , 269-285.	0.8	1
818	Hydrogen Sulfide as a Potential Therapy for COVID-19-Associated Nephropathy. , 2023, , 119-142.		0
830	COVID-19 und VTE-Prophylaxe. Springer Reference Medizin, 2024, , 1-11.	0.0	0
836	COVID-19 pathogenesis. Progress in Molecular Biology and Translational Science, 2024, , .	0.9	0
838	Central nervous system (CNS) infections in pregnancy. , 2024, , 321-347.		0
840	COVID-19-Induced Vascular Coagulopathy. , 2023, , .		0